Glenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“validates key elements” of the company’s R&D platform and unlocks significant commercial potential.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets